‘Novel treatment for advanced Parkinson’s disease’ foundMarch 17th, 2011 - 5:36 pm ICT by ANI
Washington, March 17 (ANI): A new study has indicated that a multi-center gene therapy trial for patients with advanced Parkinson’s disease demonstrated reduced symptoms of the progressive movement disorder.
The study was designed to deliver the gene for glumatic acid decarboxylase (GAD) packaged in inert viral vectors into an area of the brain called the subthalamic nucleus. GAD makes an important inhibitory chemical called GABA. The subthalamic nucleus is abnormally activated in Parkinson’s disease and this activity leads to the debilitating movement problems. The idea of the gene therapy is that the billions of AAV-2 GAD viral vectors delivered into the subthalamic nucleus will increase GABA, thereby quieting this brain region.
A total of 45 patients were enrolled in the study. Roughly half of the patients (23) were randomized into the sham surgery arm of the study, which meant that they had a surgical procedure that did not penetrate the brain, and received infusions of saline under the skin rather than the active GAD-containing viral vectors.
Everyone was assessed at one month, three months and six months after the genes were infused. Each patient in the active treatment received about a billion viral vectors. It is not clear how long the genes will pump out GAD to make GABA.
The scientists only included patients who got bilateral infusions delivered to the correct area of the brain, the subthalamic nucleus. The final analysis included 16 patients who received active (AAV2-GAD) treatment and 21 who received the sham surgery.
“This is a completely novel treatment for advanced Parkinson’s disease,” said Andrew Feigin, lead investigator of the study, associate professor of neurology and molecular medicine at The Feinstein Institute for Medical Research in Manhasset, NY.
“The treatment was remarkably well tolerated, with mostly only mild adverse events in the AAV2-GAD treated group that were felt to be unrelated to the treatment, and completely resolved,” said Feigin.
The study has been published in Lancet Neurology. (ANI)
- Trials to test gene therapy for Parkinson's disease underway - Oct 07, 2009
- Gene therapy to brain may treat major depression - Oct 21, 2010
- 'Brain pacemaker' - effective treatment for Parkinson's disease - Jun 03, 2010
- New gene therapy reverses Parkinson's symptoms - Mar 17, 2011
- Promising results of gene therapy to treat eye diseases - Aug 14, 2010
- Two genes tell how Parkinson's progresses - Feb 13, 2012
- New model paves way for drugs to fight Parkinson's disease - Feb 02, 2011
- Genes associated with binge drinking identified - Mar 01, 2011
- Drug that stops progression of Parkinson's disease in mice found - Mar 09, 2011
- Parkinson's patients find it harder to recognize emotions - Mar 04, 2010
- How quickly you learn those dance moves may be in your genes - Mar 04, 2011
- Early life stress has lasting effects on gene vital to normal brain function - Sep 29, 2010
- Brain pacemakers may help fight depression: Study - Feb 01, 2011
- Infrared light heals vision damaged by Parkisnon's - Aug 03, 2012
- Study provides new insight into Parkinson's disease - Apr 05, 2011
Tags: aav, aav2, adverse events, associate professor, billions, brain region, gene therapy trial, genes, manhasset ny, march 17, medical research, molecular medicine, neurology, novel treatment, parkinson s disease, progressive movement disorder, saline, sham surgery, subthalamic nucleus, viral vectors